Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used to treat patients with EGFR-mutated non-small cell lung cancers (NSCLCs). The association between the clinical outcomes of patients on first-line EGFR-TKIs and the efficacy of osimertinib as second-line treatment has not been previously assessed. This is our topic here.

中文翻译：

---

服用第一代 EGFR-TKI 患者的临床结果可预测奥希替尼对 EGFR T790M 突变 NSCLC 患者的益处

表皮生长因子受体酪氨酸激酶抑制剂 (EGFR-TKI) 广泛用于治疗EGFR突变的非小细胞肺癌 (NSCLC) 患者。先前尚未评估一线 EGFR-TKI 患者的临床结果与奥希替尼作为二线治疗的疗效之间的关联。这是我们这里的主题。